Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07177443 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 years later Dec 31, 2031 → Dec 31, 2035
Primary endpoint reworded 1 of 3 changed
See other at-risk trials from Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Record History

  1. Primary and study completion pushed from Dec 31, 2031 to Dec 31, 2035 Primary endpoint(s) modified · Recruitment opened · Enrollment increased: 456 → 710 participants · 5 more Show 8 more changesShow less
    • Primary endpoint(s) modified
    • Recruitment opened
    • Enrollment increased: 456 → 710 participants
    • Start date changed from estimate of Sep 25, 2025 to Sep 26, 2025
    • Eligibility criteria expanded, about 25 words
    • Secondary endpoints: details revised at 6 of 6 entries
    • Study description expanded, about 7 words
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase III trial aims to evaluate the efficacy and safety of induction chemotherapy combined with serplulimab (induction/maintenance therapy) with omission of concurrent chemotherapy in patients with locally advanced nasopharyngeal carcinoma (LA-NPC).
Trial Details
NCT Number NCT07177443
Lead Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Conditions Locally Advanced Nasopharyngeal Carcinoma
Enrollment 710 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov